It was a major case of déjà vu – Pacific Edge’s share price was in freefall as the US administrator overseeing the Kiwi firm’s access to Obamacare coverage excluded the nifty Cxbladder non-invasive bladder detection tool alongside half a dozen other tests using biomarkers.
Cracking the US market has been an anchor of the firm’s plans for years, and it’s got further than many local com...
